Dominicus Husada, MD
Dr. Soetomo General Hospital
Emerging Leaders
#2829 pts
Current Leaders
not ranked
All-Time Leaders
#38529 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2022. 4 trials as lead/chair. How it works →
Trials led — by scientific impact
An Open Label, Phase III Clinical Trial (Immunobridging Study) of INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated)) in Healthy Population Aged 12 to 17 Years Old
Phase 3UnknownDr. Soetomo General Hospital
10
impact
A Multicenter, Randomized, Double Blind, Controlled, Phase III Clinical Trial (Immunobridging Study) of Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) in Healthy Population Aged 18 Years and Above
Phase 3UnknownDr. Soetomo General Hospital
10
impact
Immunobridging Study: Immunogenicity and Safety of Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) Vaccine as Heterologue Booster in Adult Subjects in Indonesia
Early Ph 1UnknownDr. Soetomo General Hospital
9
impact
Safety and Immunogenicity of UNAIR Inactivated COVID-19 Vaccine in Healthy Populations Aged 18 Years and Above (Phase I/II)
Phase 2UnknownDr. Soetomo General Hospital
0
impact